|1.||Maniar, Manoj: 6 articles (06/2015 - 12/2008)|
|2.||Reddy, E Premkumar: 5 articles (09/2012 - 03/2005)|
|3.||Holland, James F: 4 articles (06/2015 - 09/2010)|
|4.||Wilhelm, Francois: 4 articles (06/2015 - 01/2012)|
|5.||Reddy, M V Ramana: 4 articles (09/2012 - 03/2005)|
|6.||Taft, David R: 3 articles (07/2013 - 12/2009)|
|7.||Ohnuma, Takao: 3 articles (01/2013 - 09/2010)|
|8.||Cosenza, Stephen C: 3 articles (09/2011 - 03/2005)|
|9.||Jimeno, A: 2 articles (09/2015 - 01/2009)|
|10.||Silverman, Lewis R: 2 articles (06/2015 - 09/2010)|
12/01/2009 - "Due to the short half-life and rapid clearance of the drug, administration of ON 01910.Na by continuous IV infusion is a likely treatment option for cancer patients."
04/01/2012 - "Our aim was to analyze the efficacy of ON 01910.Na against CLL cells in vitro and investigate the molecular effects of this drug on tumor biology. "
01/01/2015 - "Extensive phase I/II studies with ON01910.Na, conducted in patients with solid tumors and hematologic cancers, demonstrate excellent efficacy. "
03/27/2014 - "Clinical studies with ON01910 in cancer patients have shown efficacy along with an impressive safety profile. "
01/01/2013 - "Rigosertib (ON 01910.Na), a synthetic novel benzyl styryl sulfone, was administered to 28 patients with advanced cancer in a Phase I trial in order to characterize its pharmacokinetic profile, determine the dose-limiting toxicities (DLT), define the recommended phase II dose (RPTD) and to document any antitumor activity. "
|2.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
06/01/2015 - "A multinational pivotal phase 3 randomized clinical trial of rigosertib versus best supportive care for patients with MDS with excess blasts following prior treatment with DNMT inhibitors (ONTIME: ON 01910.Na Trial In Myelodysplastic SyndromE) has recently completed enrollment."
07/01/2013 - "Rigosertib (ON 01910.Na, Estybon) is a novel, anticancer agent undergoing phase 3 clinical trials for a lead indication against myelodysplastic syndromes (MDS). "
04/01/2012 - "ON 01910.Na (Rigosertib), a multikinase phosphoinositide 3-kinase (PI3K) inhibitor, is entering phase III trials for myelodysplastic syndrome. "
01/01/2012 - "In a Phase I/II clinical trial, 13 higher risk red blood cell-dependent myelodysplastic syndrome (MDS) patients unresponsive to hypomethylating therapy were treated with the multikinase inhibitor ON 01910.Na. "
01/01/2012 - "Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na."
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
01/29/2009 - "The novel mitotic inhibitor, ON 01910.Na, showed activity in preclinical model of pancreatic cancer. "
01/29/2009 - "Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay."
01/29/2009 - "The pupose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy. "
09/01/2015 - "Rigosertib (ON 01910.Na), a first-in-class Ras mimetic and small-molecule inhibitor of multiple signaling pathways including polo-like kinase 1 (PLK1) and phosphoinositide 3-kinase (PI3K), has shown efficacy in preclinical pancreatic cancer models. "
01/29/2009 - "ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. "
|4.||Brain Neoplasms (Brain Tumor)
09/01/2012 - "ON01910 exhibited low brain and brain tumor distribution with quasi-steady-state brain/plasma (Css(brain)/Css(plasma)) and brain tumor/plasma (Css(brain tumor)/Css(plasma)) concentration ratios of 0.03 ± 0.02 and 0.14 ± 0.08, respectively. "
12/15/2011 - "The assay was successfully applied to characterize the systemic pharmacokinetics of ON01910 as well as its disposition in brain and brain tumor in mice. "
12/15/2011 - "The purpose of the investigation was to develop a sensitive and reproducible liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to quantitate levels of ON01910 in small amounts of five biological matrices; mouse plasma, feces, urine, normal brain and brain tumor. "
12/15/2011 - "Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice."
09/01/2012 - "Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy."
|2.||polo-like kinase 1
|5.||Biological Markers (Surrogate Marker)
|6.||Proteins (Proteins, Gene)
|2.||Drug Therapy (Chemotherapy)